| Literature DB >> 32813029 |
Tarek Alsaied1,2.
Abstract
In this review, we provide a brief description of recently published articles addressing topics relevant to pediatric cardiologists. Our aim is to provide a summary of the latest articles published recently in other journals in our field. The articles address (1) cardiac resynchronization in children with symptomatic ventricular dysfunction and dyssynchrony which seems to result in higher transplant-free survival, (2) outcomes of aortic leaflet reconstruction including Ozaki procedure to repair aortic valve disease in adolescents, (3) meta-analysis for risk factors of ventricular tachycardia and death after repaired tetralogy of Fallot which reiterates the known risk factors and showed that the severity of pulmonary regurgitation is not in itself associated with outcomes although the ventricular response to regurgitation (dilation and dysfunction) is, (4) preschool promotion of healthy life style did not associate with sustained effect when evaluated later in childhood although repeated intervention seems to have a dose-related effect to promote healthy life style, (5) the lack of beneficial effects of angiotensin-converting enzyme inhibitors in the interstage period, and (6) a new phenomenon of acute heart failure and multisystem inflammatory syndrome in children temporarily related to the COVID-19 pandemic.Entities:
Keywords: Aortic regurgitation; Cardiac resynchronization therapy; Hypertrophic cardiomyopathy; Sinus venosus atrial septal defect; Stress echocardiogram; Tetralogy of fallot
Year: 2020 PMID: 32813029 PMCID: PMC7434847 DOI: 10.1007/s00246-020-02438-4
Source DB: PubMed Journal: Pediatr Cardiol ISSN: 0172-0643 Impact factor: 1.655
Summary of the 6 studies in this review
| Author | Study summary |
|---|---|
| Chubb et al | 63 patients and 63 careful propensity score-matched controls Included symptomatic ventricular dysfunction and wide QRS Transplant or death in 12% in CRT and 59% controls No CRT procedural mortality and 1 late infection CRT is feasible and effective in children and congenital patients |
| Wiggins et al | 58 patient, median age 14.8 years 40 Ozaki procedure (neo-tricuspidalization) and 18 single leaflet reconstruction Median follow-up 14 mos. 10% reintervention half for endocarditis Can be a feasible adjunctive strategy to address aortic valve disease in children |
| Possner et al | 15 studies and 7218 patients Risk factors for death/ventricular tachycardia are higher age at intracardiac repair, previous palliative shunt, and ventriculotomy, older age, longer QRS duration, right ventricular dilation/dysfunction, and left ventricular dysfunction. Pulmonary regurgitation on its own is not a risk factor Adverse ventricular remodeling and dysfunction, rather than the severity of pulmonary regurgitation, is what drives the outcomes in this patient population |
| Mazzanti et al | Total of 1216 children. Phase 1: 596 preschool healthy life promotion Phase 2: 4 mos healthy life promotion intervention in 616 and 600 controls Early intervention had only modest effect In phase 2, a dose–response effect was observed, with maximal benefit in children attending > 75% of the scheduled intervention sessions Reintervention strategies may be required at multiple stages to induce sustained health promotion effects |
| Hansen et al | 2180 infants from the national pediatric cardiology quality improvement collaborative 38% were prescribed ACE-I, more likely in centers with small volumes No difference in interstage mortality, change in atrioventricular valve regurgitation, or change in ventricular dysfunction Confirms lack of effectiveness of ACE-I in the interstage period in single ventricle |
| Belhadjer et al | 35 children, 14 centers in Europe presented with MIS-C and left ventricular dysfunction Mean age 10 and 28% comorbidities asthma and overweight 80% required inotropes and 28% ECMO support. 88% tested positive for SARS-CoV2 Resolved dysfunction in most 25/35 with IVIG and some received steroid Children may experience an acute cardiac decompensation due to severe inflammatory state following SARS-CoV-2 infection |
ACE-I angiotensin-converting enzyme inhibitor, IVIG intravenous immunoglobulins